Generic Name: ranibizumab

This medication has been identified as Cimerli 0.5 mg/0.05 mL (10 mg/mL) intravitreal injection. It is supplied by Coherus BioSciences, Inc.

Cimerli is used in the treatment of Macular Degeneration; Diabetic Macular Edema; Macular Edema; Myopic Choroidal Neovascularization; Diabetic Retinopathy and belongs to the drug class anti-angiogenic ophthalmic agents. Risk cannot be ruled out during pregnancy. Cimerli 0.5 mg/0.05 mL (10 mg/mL) intravitreal injection is not a controlled substance under the Controlled Substances Act (CSA).